.png){kind=icon}
.png){kind=icon}
Return
Histiocytic Neoplasms, Version 2.2021
.png){kind=icon}
OA
AI
DOI：10.6004/jnccn.2021.0053.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation (watch and wait) may be sufficient for select patients with mild disease. These NCCN Guidelines for Histiocytic Neoplasms include recommendations for diagnosis and treatment of adults with the most common histiocytic disorders: Langerhans cell histiocytosis, Erdheim-Chester disease, and RosaiDorfman disease.
Keywords:
LANGERHANS-CELL HISTIOCYTOSIS
ERDHEIM-CHESTER-DISEASE
ROSAI-DORFMAN-DISEASE
CENTRAL-NERVOUS-SYSTEM
CARDIAC INVOLVEMENT
MAP2K1 MUTATIONS
F-18-FDG PET/CT
HIGH PREVALENCE
ADULT PATIENTS
BRAF
Journal
J
IF:
16.4
Papers:
2.8K
Citations:
1.5W
Organization
View more organizations